Hot Investor Mandate 3: Leading Asset Manager Invests Evergreen Fund in Therapeutics, Devices, and Diagnostics

5 Jan

The proprietary venture capital and private equity arm of a leading asset management organization specializes in green-field, early and growth stage investments. With an evergreen fund structure, the firm can be flexible in terms of investment sizes (up to $250 million per deal) and horizon. The firm typically makes equity investments. The firm works with businesses based in China or with a China angle.

Within life sciences, the firm works on a wide range of technology sectors including therapeutics, medical devices, diagnostics, biotech R&D services, healthcare IT, and healthcare services. The firm is very opportunistic in terms of subsectors and indications but historically has been active in biosimilars and biotech R&D. The firm evaluates technologies based on two main criteria: meaningful impact on human health; bold and innovative ideas. The firm has no specific preference in the investment stage. However, the firm generally invests in earlier stage for therapeutics and R&D and later stage for medical devices, but seeds have been done with exceptional founding teams.

The firm is seeking companies with a strong and experienced management team. The firm is flexible when it comes to post-investment board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: